Kawa K, Konishi S, Tsujino G, Mabuchi S
Department of Pediatrics, Osaka University Hospital, Japan.
Biomed Pharmacother. 1991;45(2-3):113-6. doi: 10.1016/0753-3322(91)90130-l.
Of 125 children with acute lymphoblastic leukemia (ALL), who had been in continuous remission for three years on chemotherapy, 108 patients received biological response modifiers (BRM) such as Bestatin, N-CWS, OK-432 and/or PSK in order to prevent relapse after treatment suspension. From 20 patients who were treated with PSK, 6 relapsed within 13 months. This relapse rate was quite similar to the rate observed with those children who were off therapy (4 relapses in 17 patients within 13 months). In contrast to these 37 patients, only 3 out of 31 patients who received Bestatin (p less than 0.05) and 8 out of 57 patients who received N-CWS or OK-432 relapsed. Based on these findings, BRMs used in the present study seems to be effective to prevent relapse of leukemia among childhood ALL who have electively stopped chemotherapy.
在125名接受化疗且已持续缓解三年的急性淋巴细胞白血病（ALL）儿童中，108名患者接受了诸如抑氨肽酶B、N-胞壁酰二肽、溶链菌制剂和/或云芝多糖K等生物反应调节剂（BRM），以防止治疗中断后复发。在接受云芝多糖K治疗的20名患者中，有6名在13个月内复发。该复发率与未接受治疗的儿童（17名患者中有4名在13个月内复发）所观察到的复发率相当相似。与这37名患者不同的是，接受抑氨肽酶B治疗的31名患者中只有3名复发（p小于0.05），接受N-胞壁酰二肽或溶链菌制剂治疗的57名患者中有8名复发。基于这些发现，本研究中使用的生物反应调节剂似乎对预防选择性停止化疗的儿童ALL白血病复发有效。
